Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
7.34
-0.17 (-2.26%)
Sep 15, 2026, 4:00 PM EDT - Market closed
Verastem Revenue
Verastem had revenue of $40.08M in the quarter ending June 30, 2026, with 1,775.43% growth. This brings the company's revenue in the last twelve months to $87.53M, up 3,995.74% year-over-year. In the year 2025, Verastem had annual revenue of $30.91M with 209.14% growth.
Revenue (ttm)
$87.53M
Revenue Growth
+3,995.74%
P/S Ratio
7.59
Revenue / Employee
$858,098
Employees
102
Market Cap
664.74M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 30.91M | 20.91M | 209.14% |
| Dec 31, 2024 | 10.00M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 2.60M | 543.00K | 26.45% |
| Dec 31, 2021 | 2.05M | -86.46M | -97.68% |
| Dec 31, 2020 | 88.52M | 71.06M | 407.08% |
| Dec 31, 2019 | 17.46M | -9.26M | -34.67% |
| Dec 31, 2018 | 26.72M | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 355.17M |
| Phathom Pharmaceuticals | 239.66M |
| Valneva SE | 163.30M |
| Oculis Holding AG | 1.45M |
| Shattuck Labs | 1.00M |
| Neurogene | 925.00K |
| Altimmune | 31.00K |
VSTM News
- 1 day ago - Verastem Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 5 days ago - Verastem Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 7 days ago - Verastem to unveil new clinical data on VS-7375 - TheFly
- 7 days ago - Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers - Business Wire
- 13 days ago - Verastem Oncology to Participate in Upcoming September Investor Conferences - Business Wire
- 5 weeks ago - Verastem price target lowered to $13 from $14 at Mizuho - TheFly
- 5 weeks ago - Verastem price target lowered to $13 from $14 at Mizuho - TheFly
- 5 weeks ago - Verastem price target lowered to $12 from $14 at Guggenheim - TheFly